Non-Hodgkin Lymphoma Clinical Trials in Dallas, Texas

10 studies are recruiting for non-hodgkin lymphoma in Dallas, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

   This is a Phase 1/1b, nonrandomized, open-label, parallel assignment, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of azer-cel, an allogeneic anti-CD19 CAR T, in adults with r/r B ALL, r/r B-cell NHL and CLL/SLL.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Baylor University Medical Center, Dallas, Texas

   Locations

   15 in total

   Run by

   Imugene Limited

   See if you can join NCT03666000 on ClinicalTrials.gov

2. Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

   This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of rondecabtagene autoleucel (ronde-cel) also known as LYL314, a dual-targeting chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 and CD20 in participants with aggressive large B-cell ly…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Baylor University Medical Center, Dallas, Texas

   Locations

   35 in total

   Run by

   Lyell Immunopharma, Inc.

   See if you can join NCT05826535 on ClinicalTrials.gov

3. Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU

   This is an observational long-term follow-up (LTFU) study for subjects who previously received zamtocabtagene autoleucel, known as MB-CART2019.1.

   Stage

   Not phased

   Ages

   18 and older

   Site

   UT Southwestern Medical Center, Dallas, Texas

   Locations

   11 in total

   Run by

   Miltenyi Biomedicine GmbH

   See if you can join NCT06116110 on ClinicalTrials.gov

4. A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

   This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.

   Stage

   Not phased

   Ages

   Any age

   Site

   Medical City Dallas, Dallas, Texas

   Locations

   142 in total

   Run by

   Center for International Blood and Marrow Transplant Research

   See if you can join NCT01351545 on ClinicalTrials.gov

5. IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL

   This study is being done to determine the safety, efficacy and tolerability of a single 50 mCi dose of 131I-Apamistamab given prior to FDA approved (commercially available) infusion in patients with Relapsed or refractory (R/R) non-Hodgkin lymphoma.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Texas Southwestern Medical Center, Dallas, Texas

   Run by

   University of Texas Southwestern Medical Center

   See if you can join NCT06768905 on ClinicalTrials.gov

6. Study of SGR-1505 in Mature B-Cell Neoplasms

   The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Texas Southwestern, Dallas, Texas

   Locations

   36 in total

   Run by

   Schrödinger, Inc.

   See if you can join NCT05544019 on ClinicalTrials.gov

7. Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy

   The purpose of this transgene assay testing service is to evaluate tumor samples for transgene levels in patients who received a commercially available Bristol-Myers Squibb manufactured gene modified cellular therapy and have reported a qualifying second malignancy.

   Stage

   Not phased

   Ages

   Any age

   Site

   Ut Southwestern, Dallas, Texas

   Locations

   8 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT06357754 on ClinicalTrials.gov

8. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

   International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

   Stage

   Not phased

   Ages

   Any age

   Site

   Massive Bio SYNERGY-AI site, Dallas, Texas

   Locations

   68 in total

   Run by

   Massive Bio, Inc.

   See if you can join NCT03452774 on ClinicalTrials.gov

9. T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

   This is an open-label, dose escalation, multi-center, Phase I/II clinical trial to assess the safety of an autologous T-cell therapy (EB103) and to determine the Recommended Phase II Dose (RP2D) in adult subjects (≥ 18 years of age) who have relapsed/refractory (R/R) B-cell NHL. The study will incl…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Baylor Scott & White Research Institute, Texas Oncology, Dallas, Texas

   Locations

   2 in total

   Run by

   Estrella Biopharma, Inc.

   See if you can join NCT06343311 on ClinicalTrials.gov

10. Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL

    This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, combined with acalabrutinib for the treatment of adults with Diffuse Large B-Cell Lymphoma and Chronic Lymphocytic Leukemia. Participants must be relapsed/refractory (having failed prior therapy)

    Stage

    Phase 1

    Ages

    18 and older

    Site

    UT Southwestern Medical Center, Dallas, Texas

    Locations

    45 in total

    Run by

    Kartos Therapeutics, Inc.

    See if you can join NCT04502394 on ClinicalTrials.gov